Role of vaccine manufacturers in developing countries towards global healthcare by providing quality vaccines at affordable prices

被引:23
作者
Jadhav, S. [1 ]
Gautam, M. [1 ]
Gairola, S. [1 ]
机构
[1] Serum Inst India Ltd, Pune 411028, Maharashtra, India
关键词
Affordable healthcare; decade of vaccines; Developing Countries Vaccine Manufacturer Network; vaccines; INACTIVATED POLIO VACCINE; MENINGITIS VACCINE; INFLUENZA VACCINE; TECHNOLOGY-TRANSFER; PRODUCTION CAPACITY; CONJUGATE VACCINE; CHALLENGES; LESSONS; AFRICA; INDIA;
D O I
10.1111/1469-0691.12568
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Vaccines represent one of the greatest achievements of science and medicine in the fight against infectious diseases. Vaccination is one of the most cost-effective public health tools to prevent infectious diseases. Significant progress has been made in expanding the coverage of vaccines globally, resulting in the prevention of more than two million deaths annually. In 2010, nearly 200 countries endorsed a shared vision to extend the benefits of vaccines to every person by 2020, known as the Decade of Vaccine Initiative (DoV). Vaccine manufacturers in developing countries, as represented by the Developing Countries Vaccine Manufacturers Network (DCVMN), make a significant contribution to DoV by supplying quality vaccines at affordable prices to the people who need them most. About 70% of the global Expanded Program on Immunization (EPI) vaccine supplies are met by DCVMN. Besides EPI vaccine supplies, DCVMN is also targeting vaccines against rotavirus, Japanese encephalitis, pneumonia, human papillomavirus, meningitis and neglected tropical diseases. This article reviews the roles and contributions of DCVMN in making the vaccines accessible and affordable to all.
引用
收藏
页码:37 / 44
页数:8
相关论文
共 35 条
  • [1] Challenges To Building Capacity For Evidence-Based New Vaccine Policy In Developing Countries
    Andrus, Jon Kim
    Jauregui, Barbara
    De Oliveira, Lucia Helena
    Matus, Cuauhtemoc Ruiz
    [J]. HEALTH AFFAIRS, 2011, 30 (06) : 1104 - 1112
  • [2] [Anonymous], 2013, VACC MARK TECHN TYP
  • [3] [Anonymous], CONN CAUS
  • [4] [Anonymous], 2012, UNICEF SUPPLY DIVISI
  • [5] The global polio eradication initiative: Lessons learned and prospects for success
    Aylward, Bruce
    Tangermann, Rudolf
    [J]. VACCINE, 2011, 29 : D80 - D85
  • [6] Development and technology transfer of Haemophilus influenzae type b conjugate vaccines for developing countries
    Beurret, Michel
    Hamidi, Ahd
    Kreeftenberg, Hans
    [J]. VACCINE, 2012, 30 (33) : 4897 - 4906
  • [7] Product Development Partnerships Hit Their Stride: Lessons From Developing A Meningitis Vaccine For Africa
    Bishai, David M.
    Champion, Claire
    Steele, Michael E.
    Thompson, Lindsay
    [J]. HEALTH AFFAIRS, 2011, 30 (06) : 1058 - 1064
  • [8] CARLSON B, 2011, GENET ENG BIOTECHN N, V31, P14
  • [9] The Measles Initiative: Moving Toward Measles Eradication
    Christie, Athalia S.
    Gay, Andrea
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2011, 204 : S14 - S17
  • [10] A pandemic influenza vaccine in India: From strain to sale within 12 months
    Dhere, Rajeev
    Yeolekar, Leena
    Kulkarni, Prasad
    Menon, Ravi
    Vaidya, Vivek
    Ganguly, Milan
    Tyagi, Parikshit
    Barde, Prajakt
    Jadhav, Suresh
    [J]. VACCINE, 2011, 29 : A16 - A21